I'm not saying that improved SOC takes the control group mortality down to 60%, I'm saying that more and more white papers and statistical readouts are emerging showing lower death rates, for our cohort it could be down to 60% but it could easily be even lower:
https://www.practiceupdate.com/content/covid-19-mortality-rate-for-intubated-adults-lower-than-previously-reported/102029
https://rebelem.com/covid-19-imv-and-mortality-at-emory/#:~:text=Background%3A%20One%20of%20the%20hot,ranging%20from%2050%20to%2090%25.
There are other papers that still have it over 50%, so it's an area of uncertainty:
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03240-7/tables/2
Either way, even at the 60% readout, early efficacy depends on the Bayesian analysis criteria more than anything else (did they use a skeptical prior? or a neutral prior?). The pink column highlights show what the literature suggests may be the reasonable control group mortality rates.
60% ReadoutTable shows: 15% vs 20% treated group mortality, skeptical vs neutral prior at different control group mortality rates
35% 40% 50% 60% 65% 70% 75% 80% 85% 15% skeptical 0.373 0.511 0.742 0.895 0.942 0.973 0.990 0.997 0.999 15% uninformed 0.932 0.985 0.999 0.999 0.999 0.999 0.999 0.999 0.999 20% skeptical 0.188 0.303 0.545 0.757 0.841 0.907 0.953 0.981 0.994 20% uninformed 0.708 0.890 0.992 0.999 0.999 0.999 0.999 0.999 0.999
you're right that we don't know if improved SOC will help the treated group or not, but the scope by which it can help the treated group is much lower than for the untreated group. It's much easier to have a big effect on saving lives in a group with 80-85% mortality than in a group with only 15% mortality... law of diminishing returns and all that...
@LearningEachDay - Cases are up, but there's not yet the same increase in hospitalisations and deaths. We see some smaller changes to those, so it's a question of if there is a lag there, or if the improved SOC cascades down the line a little:
https://covidtracking.com/data
I hope I am wrong, and you are right... but I don't see a lot of evidence yet to support the enrollment concluding by year's end.
- Forums
- ASX - By Stock
- MSB
- Overwhelming efficacy - the stats required
MSB
mesoblast limited
Add to My Watchlist
0.30%
!
$1.66

Overwhelming efficacy - the stats required, page-496
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.66 |
Change
0.005(0.30%) |
Mkt cap ! $2.121B |
Open | High | Low | Value | Volume |
$1.65 | $1.67 | $1.63 | $2.856M | 1.724M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
37 | 87562 | $1.66 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.67 | 43860 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 77002 | 1.660 |
19 | 93211 | 1.655 |
19 | 156478 | 1.650 |
13 | 105372 | 1.645 |
13 | 86430 | 1.640 |
Price($) | Vol. | No. |
---|---|---|
1.665 | 45244 | 18 |
1.670 | 115679 | 22 |
1.675 | 68264 | 15 |
1.680 | 154103 | 12 |
1.685 | 25258 | 8 |
Last trade - 15.58pm 14/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |